This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Mike Mitka

JAMA. 1999;281:1258-1260.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New Orleans—People with intractable angina received discouraging and encouraging news from researchers presenting data at the American College of Cardiology's annual meeting held here in early March.

In the headline-grabbing field of gene transfer, results of the first large, double-blind, placebo-controlled trial of therapeutic angiogenesis in patients with severe angina showed, essentially, that the therapy worked only as well as the placebo. While researchers presenting the data warned that their results are preliminary and insisted that it's too early to dismiss gene therapy as a treatment for angina, Genentech Inc, manufacturer of the tested recombinant human vascular endothelial growth factor (rhVEGF 165), called the results "disappointing."

But on another front, patients with angina who are not candidates for coronary artery bypass graft surgery or angioplasty may be offered relief through a laser treatment that doesn't require cutting open the chest. Last year, the US Food and Drug . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?